NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled "Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments Pipeline” published by P&S Market Research, HAE currently exhibits a proliferating pipeline with 20 drug candidates.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis/report-sample
The study analyzed that HAE therapeutics pipeline comprises 20 drug candidates in different stages of development. HAE is a disease characterized by repeated incidents of swelling (angioedema). Some of the common body areas that get affected due to this disease include intestinal tract, face, limbs, and airway. The stress can cause a heart attack, but most often in the patients suffering from HAE, the swelling occurs with an unknown trigger.
Most of the companies have developed novel technologies for the development of drug candidates for the treatment of HAE. For instance, Arrowhead Pharmaceuticals, Inc. has established a drug discovery, and development platform that has broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies. These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk, relative to traditional approaches. These technological advancements act as a key driver for pipeline growth.
Access Report Summary at: https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis
The positive clinical results of HAE drug candidates are driving the pipeline growth. For instance, Attune Pharmaceuticals, Inc., announced the Pre-Clinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. Studies demonstrated that ATN-249 was highly selective and potent at plasma kallikrein inhibition in both biochemical inhibition and contact activation assays. Therefore, the positive clinical results of the compounds under the development for the treatment of HAE, are fueling the research and development investment being made by the players developing drugs for the treatment of HAE.
Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc.
Make Enquiry Before Buying: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hereditary-angioedema-therapeutics-pipeline-analysis
Browse Related Reports:
Cyclin-Dependent Kinase Inhibitors Therapeutics Pipeline Analysis 2017
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
https://www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis
Diabetic Foot Ulcer Therapeutics Pipeline Analysis 2017
Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where neuropathy dominates and neuroischemic foot where occlusive vascular disease is the main factor. Diabetic neuropathy, peripheral artery disease and consequent trauma of the foot are the major risk factors for diabetic foot ulcer. The motor and sensory nerve damage can cause muscle weakness, paresis and atrophy in diabetic patients. Diabetic foot ulcer can be assessed by physical examination of the skin for the vascular, neurological, and musculoskeletal systems. Additionally, this examination also involves the assessment of perception of superficial pain, and temperature. Neuropathic disability score is assessed to evaluate the risk of occurrence of neuropathic ulceration.
https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com